Weight loss jabs are the newest craze to shed a couple of kilos. With drugs resembling Ozempic and Wegovy (semaglutide), their effect has been dramatic, causing users to Up to 15% damage Average their body fat.
Semaglutide, which is a glucagon-like peptide 1 (GLP-1 receptor agonist medication) mimics Natural gut hormone action Which is released after we eat.
This gut hormone stimulates a lot of physiological responses that play a job in regulating body weight, resembling releasing insulin to assist control blood sugar levels, slowing stomach emptying (so we feel fuller longer) and even telling the brain’s hunger centers to suppress hunger.
But as effective as GLP-1 drugs are, not everyone who uses them will lose enough weight. The so-called “non-respondents” are those that Less than 5% loss After about their body weight Six months Treatment at essentially the most tolerated dose. Research suggests that Between 10% and 30% Patients fit into this group.
Many people who find themselves labeled as non-responders to GLP-1 receptor agonists resembling semaglutide don’t take the medication appropriately or stop treatment before achieving an adequate therapeutic effect. Studies show. Up to 20-60% of people People stop treatment throughout the first 12 months, and the drug is widely utilized in doses lower than really useful.
sure Metabolic problems As with insulin resistance, where the body’s cells stop responding properly to insulin, semaglutide may stop working. Sleep disturbance It may block the drug’s effects, as lack of sleep delays the discharge of the body’s natural GLP-1 hormone.
People taking other medicines, eg Corticosteroids And Psychiatric drugs (resembling antidepressants) that could cause weight gain can also find that GLP-1 drugs don’t work as well for them.
But these usually are not the one the explanation why an individual could also be labeled non-responsive.
Interestingly, sex may play a job in how an individual responds to those drugs, with studies showing that ladies taking semaglutide consistently lost more weight than men.
A review of 47 randomized controlled trials involving greater than 23,000 patients found that The biggest effect is weight loss GLP-1 drugs were shown in participants who were young, female and never diagnosed with diabetes (in order that they were higher off). Insulin sensitivity).
One reason women respond higher could also be due to them. High estrogen levels. This hormone improves insulin sensitivity and stimulates the discharge of GLP-1.
Millie F/Shutterstock
Another reason some people respond poorly to GLP-1 drugs is their genetic makeup.
Scientists have identified variants within the gene coding for the enzyme. PAM (peptidyl-glycine alpha-amidating monooxygenase) which causes GLP-1 resistance. This genetic mutation is carried by about 10% of the population.
Individuals with this genetic mutation have high circulating levels of GLP-1 but without the expected biological effect. This implies that more GLP-1 hormone is required to realize the identical response in people without the mutation. This indicates clear resistance to the hormone.
Research that checked out the genetics of nearly 28,000 people taking GLP-1 drugs also identified this. Genetic problems Another set of receptor genes called GLP-1R and GEPR.
This genetic issue led to differences in each weight reduction and unintended effects. People who had these genetic problems had the next body mass index (BMI) and body mass on average, and were more more likely to develop type 1 diabetes and other metabolic problems. Such genetic differences may explain why some people fail to drop some pounds when taking a GLP-1 drug.
Another factor that will contribute to non-responders is expounded to the causes of obesity itself. Our body works on its basis. Four different types of hunger. If a drug targets something that isn’t the underlying reason for an individual’s obesity, the response seen will likely be small.
The first type is our basic slow-burn appetite, which is the minimum variety of calories our body absolutely must eat to operate (also often known as our metabolic rate). Another variety of hunger is the hungry gut, which has to do with the actual, physical need for food. gave The way we eat It will also be driven by our brain (often known as the hungry mind, where we eat out of habit or stress) or our emotions (often known as emotional hunger, where we eat to address how we feel).
For patients with anorexia nervosa, GLP-1 medications don’t address the underlying reason for the person’s overeating anxiety and depression. According to an observational study Conducted in Japan, impulsive eaters were less more likely to see significant weight change when using GLP-1 drug treatment.
Integrating cognitive behavioral therapy can due to this fact be vital for many who struggle. Emotional hunger and are used as GLP-1 drugs. for A hungry gut Patients, a high protein, high fiber weight loss program can increase the effectiveness of the drug.
for Patients with hungry brainsswitching to dual agonists resembling tarzapatide (known commercially as Monjaro), which targets two digestive hormones, GLP-1 and glucose-dependent insulinotropic peptide (GIP), could also be useful. for Slow burn Appetite, resistance training can increase resting metabolic rate.
Although weight reduction drugs have proven effective for many individuals, the indisputable fact that they don’t work for everybody shows how vital it’s to maneuver toward developing the suitable obesity medicine. This involves analyzing a patient’s unique genes and lifestyle patterns to match them. The right medicine. Although genetic testing for variants related to non-response isn’t common, it represents the following step in helping to make sure that patients are given the treatments that work best for them.